$24.30
2.75%
Nasdaq, Aug 22, 10:00 pm CET
ISIN
US55910K1088
Symbol
DNTH

Magenta Therapeutics Inc Stock price

$24.30
+3.56 17.16% 1M
+2.70 12.50% 6M
+2.50 11.47% YTD
-3.32 12.02% 1Y
-2.42 9.06% 3Y
-85.14 77.80% 5Y
-208.02 89.54% 10Y
-208.02 89.54% 20Y
Nasdaq, Closing price Fri, Aug 22 2025
+0.65 2.75%
ISIN
US55910K1088
Symbol
DNTH
Industry

Key metrics

Basic
Market capitalization
$782.2m
Enterprise Value
$524.8m
Net debt
positive
Cash
$257.4m
Shares outstanding
32.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
161.3 | 268.3
EV/Sales
108.2 | 180.0
EV/FCF
negative
P/B
2.6
Financial Health
Equity Ratio
94.2%
Return on Equity
-24.1%
ROCE
-42.5%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$4.9m | $2.9m
EBITDA
$-129.3m | -
EBIT
$-129.9m | $-144.0m
Net Income
$-114.8m | $-112.6m
Free Cash Flow
$-100.4m
Growth (TTM | estimate)
Revenue
18.0% | -53.3%
EBITDA
-87.2% | -
EBIT
-88.9% | -41.3%
Net Income
-102.5% | -32.5%
Free Cash Flow
-316.4%
Margin (TTM | estimate)
Gross
-
EBITDA
-2,664.2% | -
EBIT
-2,676.6%
Net
-2,364.1% | -3,863.2%
Free Cash Flow
-2,067.6%
More
EPS
$-3.2
FCF per Share
$-3.1
Short interest
24.3%
Employees
78
Rev per Employee
$80.0k
Show more

Is Magenta Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,019 stocks worldwide.

Magenta Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a Magenta Therapeutics Inc forecast:

18x Buy
95%
1x Hold
5%

Analyst Opinions

19 Analysts have issued a Magenta Therapeutics Inc forecast:

Buy
95%
Hold
5%

Financial data from Magenta Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
4.85 4.85
18% 18%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 30 30
18% 18%
611%
- Research and Development Expense 105 105
120% 120%
2,168%
-129 -129
87% 87%
-2,666%
- Depreciation and Amortization 0.60 0.60
294% 294%
12%
EBIT (Operating Income) EBIT -130 -130
89% 89%
-2,679%
Net Profit -115 -115
102% 102%
-2,366%

In millions USD.

Don't miss a Thing! We will send you all news about Magenta Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Magenta Therapeutics Inc Stock News

Neutral
The Motley Fool
18 days ago
Dianthus Therapeutics (DNTH -6.08%), a clinical-stage biotech developing therapies for autoimmune neuromuscular diseases, reported second quarter results on August 7, 2025. Net loss per share (GAAP) was $(0.88).
Neutral
GlobeNewsWire
18 days ago
Phase 2 MaGic trial of claseprubart (DNTH103) in generalized Myasthenia Gravis (gMG) top-line results anticipated in September 2025; the first of three catalysts for the claseprubart neuromuscular franchise by YE'26
Neutral
GlobeNewsWire
3 months ago
NEW YORK and WALTHAM, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the Company's participation in the Jefferies Global Healthcare Conference. Marino Garcia, Chief Executive Officer, will ...
More Magenta Therapeutics Inc News

Company Profile

Magenta Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of novel medicines for bone marrow transplants. It offers platform that focuses on critical areas of transplant medicine. The company was founded by David Scadden, Derrick Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner in June 2015 and is headquartered in Cambridge, MA.

Head office United States
CEO Marino Garcia
Employees 78
Founded 2015
Website dianthustx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today